Provided by Tiger Trade Technology Pte. Ltd.

ALPHAMAB-B

8.455
+0.3254.00%
Volume:2.48M
Turnover:21.27M
Market Cap:8.19B
PE:-60.41
High:8.860
Open:8.230
Low:8.230
Close:8.130
52wk High:15.750
52wk Low:6.230
Shares:969.00M
HK Float Shares:969.00M
Volume Ratio:2.21
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.140
ROE:-6.43%
ROA:-4.42%
PB:4.11
PE(LYR):-60.41
PS:12.41

Loading ...

HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%

Tiger Newspress
·
Yesterday

Alphamab's KN026 Combination Therapy for First-Line HER2-Positive Advanced Breast Cancer Receives NMPA Filing Acceptance

Stock News
·
Aug 18

Alphamab Oncology Says China NMPA Accepts Anbenitamab NDA for First-Line HER2+ Advanced Breast Cancer

Reuters
·
Aug 18

Alphamab Oncology - Nmpa Accepts Nda for Anbenitamab (Kn026) with Hb1801 for Her2+ Advanced Breast Cancer

THOMSON REUTERS
·
Aug 18

Alphamab Oncology Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 12

Alphamab Oncology Licenses Cancer Drug Candidate to Pathos AI for Up to $2.09 Billion

MT Newswires Live
·
Aug 05

Alphamab Oncology (ALPHAMAB-B) Reports Stable Share Capital and Option Movements for July 2026

Bulletin Express
·
Aug 05

CSPC Pharma Unit, Alphamab Oncology's Breast Cancer Drug Application Granted Priority Review in China

MT Newswires Live
·
Aug 04

ALPHAMAB-B's Novel Drug Application for Anniutuo (KN026) in HER2-Positive Breast Cancer Neoadjuvant Therapy Accepted by Chinese Regulator

Stock News
·
Aug 04

Alphamab Oncology receives NMPA priority review for Anbenitamab NDA in neoadjuvant HER2+ breast-cancer therapy

Bulletin Express
·
Aug 04

Alphamab Oncology Says NMPA Accepts NDA for Anbenitamab (kn026)

Reuters
·
Aug 04

Alphamab Oncology - Nmpa Accepts Nda for Anbenitamab (Kn026) as Neoadjuvant Her2+ Breast Cancer Treatment

THOMSON REUTERS
·
Aug 04

HK-Listed Alphamab Hits 2-Month High on Breast Cancer Drug Licensing Deal

Reuters
·
Aug 04

ALPHAMAB-B Surges Over 12% in Morning Trade Following $2.1 Billion TROP2/HER3 Dual Antibody ADC Export Licensing Deal

Deep News
·
Aug 04

Alphamab Oncology - Jiangsu Alphamab to Receive $125 Mln Upfront, up to $2.09 Bln Total from Pathos AI

THOMSON REUTERS
·
Aug 04

Alphamab Oncology - Unit Granted Pathos AI Exclusive License to Commercialize Jskn016 in Territories Outside Chinese Mainland, HK, Macau, Taiwan

THOMSON REUTERS
·
Aug 04

Alphamab Oncology Licenses Jskn016 Ex-China Rights to Pathos AI for up to USD 2.09 Billion

Reuters
·
Aug 04

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on Jskn016, a First-in-Class Trop2/Her3 Bispecific ADC

THOMSON REUTERS
·
Aug 04

Alphamab Oncology Announces Approval from CDE for Jskn033 to Initiate a Phase III Clinical Study

Reuters
·
Aug 04

ALPHAMAB-B wins CDE green light to start Phase III trial of subcutaneous bispecific ADC/PD-L1 combo JSKN033 for hard-to-treat cervical cancer

Bulletin Express
·
Aug 03